Biohaven Pharma (BHVN) Misses Q2 EPS by 49c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/3/2026
- Wall Street ends lower as Middle East tensions escalate
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Broadcom's sales and AI chip forecast comes in below expectations, shares tumble
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Oil gains as Middle East hostilities flare
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Alphabet plans $80 billion equity raise to fund AI infrastructure expansion, Berkshire Hathaway to invest $10 billion
- Alphabet plans $80 billion raise for AI, backed by Buffett’s Berkshire
- After-Hours Stock Movers: AVGO, CRWD, FIVE, AI, TLYS, NTSK,
- After-Hours Stock Movers: PANW, CRWD, ZS, GTLB, ULTA
- After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
- After-Hours Stock Movers: DELL, MDB, AEO, NTAP, GAP, S, ADSK
- After-Hours Stock Movers: CRM, MRVL, SNOW, HPQ, DDOG, MDB, P, SNPS, BRZE, NCNO
UBS Downgrades Biohaven Pharmaceutical Holding (BHVN) to Neutral
August 10, 2021 7:01 AM EDTUBS analyst Esther Rajavelu downgraded Biohaven Pharmaceutical Holding (NYSE: BHVN) from Buy to Neutral with a price target of $109.00 (from $108.00).
The analyst comments "We are moving to Neutral from Buy following a strong 1H21 stock performance for BHVN, primarily driven by Nurtec... More
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $140 at Cowen
August 9, 2021 10:49 AM EDTCowen analyst Ken Cacciatore raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $140.00 (from $130.00) while maintaining an Outperform rating.
The analyst commented, "The Q2 performance validates our and our consultants initial views of the product and depth of need, and it... More
